H. Johannsdottir

发表

Somatic deletions in hereditary breast cancers implicate 13q21 as a putative novel breast cancer susceptibility locus.

E. Gillanders, D. Stephan, H. Grönberg, 2000, Proceedings of the National Academy of Sciences of the United States of America.

Alectinib versus chemotherapy in crizotinib-pretreated anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer: results from the phase III ALUR study

S. Novello, R. Dziadziuszko, J. Wolf, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Chromosome 5 imbalance mapping in breast tumors from BRCA1 and BRCA2 mutation carriers and sporadic breast tumors

Å. Borg, B. Agnarsson, R. Barkardottir, 2006, International journal of cancer.

Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study.

T. Ciuleanu, L. Stelmakh, S. Cicėnas, 2012, The Lancet. Oncology.

A genomic map of a 6-Mb region at 13q21-q22 implicated in cancer development: identification and characterization of candidate genes

Heli Nevanlinna, Therese Sandberg, Dietrich A. Stephan, 2002, Human Genetics.

Lack of HIN-1 methylation in BRCA1-linked and "BRCA1-like" breast tumors.

A. Richardson, Å. Borg, K. Polyak, 2003, Cancer research.

A germline variant in the TP53 polyadenylation signal confers cancer susceptibility

Kari Stefansson, Brian T Helfand, Torben Hansen, 2011, Nature Genetics.

Deletions on chromosome 4 in sporadic and BRCA mutated tumors and association with pathological variables.

Å. Borg, H. Olsson, B. Agnarsson, 2004, Anticancer Research.

1299O_PRPrimary results from the phase III ALUR study of alectinib versus chemotherapy in previously treated ALK+ non-small-cell lung cancer (NSCLC)

S. Novello, R. Dziadziuszko, J. Mazières, 2017 .

Vesicular Stomatitis Virus Entry Host Cell Factors and Functions Involved In

A. Helenius, J. Kartenbeck, R. Mancini, 2022 .

1346PCNS efficacy results from the phase III ALUR study of alectinib vs chemotherapy in previously treated ALK+ NSCLC

S. Novello, R. Dziadziuszko, J. Mazières, 2017 .

Host Cell Factors and Functions Involved in Vesicular Stomatitis Virus Entry

A. Helenius, J. Kartenbeck, R. Mancini, 2008, Journal of Virology.

First-in-human, dose-escalation, phase (ph) I trial to evaluate safety of anti-Axl antibody-drug conjugate (ADC) enapotamab vedotin (EnaV) in solid tumors.

I. Vergote, Juanita Lopez, F. Thistlethwaite, 2019, Journal of Clinical Oncology.